Fragile X Syndrome (FXS)

Spinogenix’s Fragile X Syndrome drug shows normalisation of brain function

The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients

Restoring Lost Synapses in ALS, Fragile X and More with Spinogenix’s Dr. Peter Vanderklish — Episode 233

SPG601 calms brain activity in men with fragile X, helping them to focus

Spinogenix Receives Positive FDA Feedback for SPG601 in Fragile X Syndrome

SPG601 granted orphan drug status in EU for treating fragile X

SPG601 found to reduce measure of abnormal brain activity in fragile X

FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of FXS

FDA Designation for SPG601 Highlights New Hope for FXS Treatment

Novel BK Channel Activator Fast Tracked for Fragile X Syndrome